NCT03044080View on ClinicalTrials.gov

Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

September 30, 2017

Conditions
Stroke RehabilitationStroke Rehabilitation Spasticity Management
Interventions
DRUG

IncobotulinumtoxinA

Three consecutive injections of 200-300 units of IncobotulinumtoxinA (Xeomin ®) under ultrasound guidance. The IncobotulinumtoxinA will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.

DRUG

OnabotulinumtoxinA

ree consecutive injections of 200-300 units of OnabotulinumtoxinA (Botox ®) under ultrasound guidance. The BoNT/A will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.

Trial Locations (1)

08024

Hospital de l'Esperança, Barcelona

All Listed Sponsors
lead

Parc de Salut Mar

OTHER

NCT03044080 - Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot | Biotech Hunter | Biotech Hunter